Ubrogepant
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2019
- First approval year
- 2019
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Ubrogepant
- Molecular weight
- 549.55
- Structure (SMILES)
- C[C@@H]1[C@H](c2ccccc2)C[C@H](NC(=O)c2cnc3c(c2)C[C@@]2(C3)C(=O)Nc3ncccc32)C(=O)N1CC(F)(F)F
- ubrelvy
- Ubrelvy
- mk 1602
- MK-1602
- ubrogepant
- Ubrogepant
- ubrogepant [INN]
- UBROGEPANT [MI]
- UBROGEPANT [ORANGE BOOK]
- UBROGEPANT [USAN]
- Ubrogepant [WHO-DD]
- Ubrogepant 100 mg
- ubrogepant anhydrous
- Ubrogepant anhydrous
- ubrogepant inn
- ubrogepant mi
- ubrogepant orange book
- ubrogepant usan
- ubrogepant who dd
- ATC classification codes
- N02CD04
Sources for recorded values
- CAS registry numbers
- 1374248-77-7
- ChEMBL ID
- CHEMBL2364638
- InChIKey
- DDOOFTLHJSMHLN-ZQHRPCGSSA-N
- PubChem compound IDs
- 68748835
- RxNorm IDs (RxCUI)
- 2268216
- FDA ingredient codes (UNII)
- AD0O8X2QJR
- Applicant
- ABBVIE
- Approval date
- 23 Dec 2019
- Application number
- NDA211765
- Patents
- 16
- Designations
- 0
- Earliest recorded loss of exclusivity
- 22 Dec 2041
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Pharmacology name
- ubrogepant
- Type
- Synthetic organic
- Drug name stem
- -gepant
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Oral
- Action
- Antagonist
- Action type
- Antagonist
- Target
- CGRP receptor
- Gene symbol
- RAMP1
- Protein identifier
- O60894
- Median affinity
- 10.8
- Affinity units
- pKB
- Action
- Antagonist
- Action type
- Antagonist
- Target
- CGRP receptor
- Gene symbol
- CALCRL
- Protein identifier
- Q16602
- Median affinity
- 10.8
- Affinity units
- pKB
- Mechanism
- Calcitonin gene-related peptide type 1 receptor antagonist
- Action type
- Antagonist
- Target
- Calcitonin gene-related peptide type 1 receptor
- Protein identifier
- Q16602
Open Targets mechanisms
- Mechanism
- Calcitonin gene-related peptide type 1 receptor antagonist
- Action type
- Antagonist
- Target
- Calcitonin gene-related peptide type 1 receptor
DrugCentral mechanisms
- Action type
- Antagonist
- Gene symbol
- CALCRL
- Protein identifier
- Q16602
- Organism
- Homo sapiens
- Target development level
- Clinical
Investigated indications
- Condition
- Migraine Disorders
- Highest recorded phase
- 4
- Condition identifier
- MONDO:0005277
- Subject identifier
- D008881
- Condition identifier
- EFO_0008008
- Condition identifier
- MONDO_0005277
- Condition identifier
- MONDO_0005277
- Highest recorded phase
- 4
- Event
- facial paralysis
- Reports
- 3
- Reporting signal score
- 9.88568
- Event
- mast cell degranulation present
- Reports
- 1
- Reporting signal score
- 10.0887
- Event
- migraine
- Reports
- 8
- Reporting signal score
- 18.7323
- NCT01613248
- NCT01657370
- NCT02828020
- NCT02867709
- NCT02873221
- NCT04179474
- NCT04492020
- NCT04818515
- NCT05125302
- NCT05127954
- NCT05264129
- NCT05503082
- NCT06417775
- Dose
- 50-100mg
- Route
- Oral
- How often
- As needed
- Maximum 200mg per 24 hours
- Second dose at least 2 hours after initial dose
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 104.29
- Calculated partition coefficient (ALogP)
- 3.53
- Calculated partition coefficient (XLogP)
- 3.1
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 1
- Rotatable bonds
- 4
- Heavy atoms
- 40
- Molecular formula
- C29H26F3N5O3
- Monoisotopic mass
- 549.19877419
- Natural product
- No
- 0023-6498
- 0023-6501
- Recorded assays
- 10
- Active assays
- 6
Active assay types
- Confirmatory
Related records
Trials (19)
- A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)
- A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)
- A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine
- An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
- Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine
- Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine
- Evaluation of the Efficacy of Almotriptan and Ubrogepant for the Acute Treatment of Migraine
- Influence of Ubrogepant and Sumatriptan on the Dermal Blood Flow Response to Histamine, Cinnamaldehyde and Capsaicin
- Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)
- Migraine Medication Effects on Urinary Symptoms
- Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
- Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
- Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers
- Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
- Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine
- Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine
- Study to Assess How Different Oral Formulations of Ubrogepant Move Through the Body in Healthy Adult Participants
- Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants
- Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies
Approved for (1)
Targets (1)
- CALCRL Calcitonin gene-related peptide type 1 receptor antagonist